The European Union’s medicines regulator has approved new sites for the manufacture of the Pfizer-BioNTech, Moderna and AstraZeneca coronavirus vaccines, in a bid to significantly boost Europe’s supply of COVID-19 jabs. In
A late-stage US clinical trial of the Oxford-AstraZeneca coronavirus vaccine found the jab was effective in preventing COVID-19, while also being safe to use, easing concerns over blood clotting incidents in Europe.
With many parts of Europe going back into lockdown while Cyprus struggles to throw the shackles off a second national emergency, the Oxford-AstraZeneca vaccine debate rumbles on. It is hard to dismiss
Cyprus resumed vaccinations of the AstraZeneca COVID-19 vaccine on Friday after the European Medicines Authority (EMA) ruled it was safe and effective, the Health Ministry said. Authorities had suspended administering the jab
Cyprus will resume its inoculations using the AstraZeneca vaccine, having suspended the programme on Monday following a European investigation into about 40 cases of blood clots in people who had received the
Cyprus’ decision to suspend COVID-19 inoculations using the AstraZeneca vaccine has disrupted 7,500 appointments for first and second jabs, a Health Ministry official said on Tuesday. This will be a major setback
Cyprus halted the use of the AstraZeneca/Oxford jab as part of its national inoculation programme until an investigation is concluded by the European Medicines Agency on Thursday into 40 cases of blood
Cyprus’ inoculation programme has picked up speed as vaccine deliveries in March have increased, with authorities vaccinating 10% of the population. The health authorities said on Friday that they are pushing ahead
Cyprus has held back a batch of AstraZeneca COVID-19 vaccines which Austria put on ice after the death of a woman from blood clots and hospitalisation of a second person days after
Hopes that the EU’s struggling vaccination rollout programmes against the coronavirus will pick up speed were reignited as a fifth COVID-19 vaccine came under review for approval, Germany’s CureVac. If given the